Anagrelide
- Generic Name
- Anagrelide
- Brand Names
- Xagrid, Agrylin, Anagrelide Viatris (previously Anagrelide Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C10H7Cl2N3O
- CAS Number
- 68475-42-3
- Unique Ingredient Identifier
- K9X45X0051
- Background
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. busulfan, hydroxyur...
- Indication
Anagrelide is indicated for the treatment of thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis. It is also beneficial in the amelioration of thrombocythemia symptoms including thrombo-hemorrhagic events.
- Associated Conditions
- Thrombocythemia
- Associated Therapies
- -
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT06079879
- Locations
- 🇨🇳
Anhui Provincial Hospital ( Site 3513), Hefei, Anhui, China
🇨🇳Peking University Third Hospital-Hematology ( Site 3502), Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital Of Fujian Medical University ( Site 3525), Quanzhou, Fujian, China
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
- Conditions
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- PharmaEssentia
- Target Recruit Count
- 174
- Registration Number
- NCT04285086
- Locations
- 🇯🇵
University of Yamanashi Hospital, Chuo, Yamanashi, Japan
🇯🇵Ehime University Hospital, Toon, Ehime, Japan
🇯🇵Mie University Hospital, Tsu, Mie, Japan
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
- Conditions
- Interventions
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT03123588
- Locations
- 🇺🇸
Columbia Weill Cornell Cancer Centers - Herbert Irving Comprehensive Cancer Center (HICCC), New York, New York, United States
🇺🇸Ventura County Hematology-Oncology Specialists, Oxnard, California, United States
🇺🇸Tift Regional, Tifton, Georgia, United States
The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
- Conditions
- Interventions
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 13
- Registration Number
- NCT02962388
- Locations
- 🇫🇷
FILO, Tours, France
Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2010-10-06
- Lead Sponsor
- AOP Orphan Pharmaceuticals AG
- Registration Number
- NCT01065038
- Locations
- 🇩🇪
Center Munich, Munich, Bavaria, Germany
🇨🇿Center Olomouc, Olomouc, Czech Republic
🇵🇱Center Gdansk, Gdansk, Poland
A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Shire
- Target Recruit Count
- 150
- Registration Number
- NCT00202644
- Locations
- 🇭🇺
Petz Aladar County Teaching Hospital, Gyor, Hungary
🇵🇹Hospitals da Universidade de Coimbra, Coimbra, Portugal
🇫🇷Hopital Saint Louis - Centre d'Investigation Clinique, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.